PARP inhibitors and newly second primary malignancies in cancer patients: a systematic review and safety meta-analysis of placebo randomized controlled trials

Author(s):  
P.-M. Morice ◽  
I. Ray-Coquard ◽  
K.N. Moore ◽  
V. Diéras ◽  
J. Alexandre
Sign in / Sign up

Export Citation Format

Share Document